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EDITORIALEpithelial Reactive Oxygen Species and Risk for Very Early Onset
Inﬂammatory Bowel Diseaseurrent evidence suggests that the inﬂammatoryFigure 1. The article by Hayes et al3 identiﬁes novel
mutations in two genes, NOX1 and DUOX2, in patients
with very early onset IBD. Functional analyses suggest that
these mutations disrupt production of reactive oxygen spe-
cies (ROS) and thereby impair host defense to enteric path-
ogens, including Campylobacter spp.Cbowel diseases (IBD) Crohn’s disease and ulcerative
colitis (UC) are caused by a complex interaction between
host genetic background, microbial shifts, and environ-
mental cues leading to inappropriate chronic activation of
the mucosal immune system. The development of antimi-
crobial seroreactivity and chronic Crohn’s disease–like in-
testinal inﬂammation during the ﬁrst decade of life in
children with the inherited disorder of phagocyte function
chronic granulomatous disease (CGD) has suggested
that loss-of-function in phagocyte reactive oxygen species
(ROS) production is likely to be a fundamental mechanism
of very early onset (VEO, age <6 years at diagnosis) IBD
pathogenesis.1
Dhillon et al2 had previously reported that rare loss-of-
function variants in the genes that comprise the phagocyte
nicotinamide adenine dinucleotide phosphate (NADPH) ox-
idase 2 (NOX2) complex are associated with increased risk
for VEOIBD. Although these variants do not reduce ROS
production to the degree observed in CGD or cause overt
immune deﬁciency, the functional defect may be sufﬁcient
to affect intestinal microbial responses. In the current study,
the authors have now tested the hypothesis that genetic
variants reducing function of the intestinal epithelial
NADPH oxidases, NOX1 and DUOX2, are also associated with
VEOIBD.3 They identiﬁed rare loss-of-function missense
mutations in NOX1 or DUOX2 in ﬁve of 209 VEOIBD patients
tested. Importantly, these missense variants were associ-
ated with reduced epithelial ROS production and defective
host resistance to the bacterial pathogen Campylobacter
jejuni (Figure 1). The study is the ﬁrst to link NOX1 variants
to human disease, and establishes NOX1 and DUOX2 as risk
genes for VEOIBD. The authors conclude that defective in-
testinal epithelial ROS production is therefore a risk factor
for the development of VEOIBD, likely by impairing micro-
bial defenses.
The profound reduction in phagocyte ROS production
due to the NADPH oxidase genetic variants that cause CGD is
associated with increased susceptibility to bacterial and
fungal infections. In fact, the use of anti–tumor necrosis
factor agents for CGD colitis is limited by a high risk for
fungal infection. However, ROS also function as signaling
molecules, and CGD myeloid cells have recently been shown
to exhibit a hyperinﬂammatory phenotype.1 The speciﬁc
mechanisms remain under investigation, but this may
involve monocyte inﬂammasome activation and preferential
induction of proinﬂammatory TH17 cells. Conversely,
enterocyte NOX1 via ROS production has recently been
shown to transduce the microbial signals that promote
epithelial wound healing.4 It will be of interest to determine
whether the reduction in epithelial ROS production inCellular and Molecular Gastroenterology and Hepatology 2015;1:456–4VEOIBD patients with NOX1 or DUOX2 loss-of-function
variants is also associated with impaired wound healing
and/or enhanced production of inﬂammatory chemokines,
which would promote mucosal ulceration and leukocyte
recruitment.
The pediatric IBD collaborative research group, Pediatric
Resource Organization for Kids with Inﬂammatory Intesti-
nal Digestive Diseases (PRO-KIIDS), has recently reported
the results of a combined clinical, genetic, and high-
throughput mucosal transcriptomic and microbial commu-
nity proﬁling at the time of IBD diagnosis in treatment-naïve
pediatric Crohn’s disease and UC patients.5 A progressive
increase in an ileal DUOX2 gene coexpression signature was
detected in association with expansion of Proteobacteria
taxa across all forms of IBD (UC, colon-only Crohn’s disease,
and ileal Crohn’s disease). These ﬁndings of substantially
increased ileal expression of both DUOX2 and its binding
partner DUOXA2 in IBD suggest a central role for the dual
oxidase DUOX2 in this setting. Indeed, DUOX2 interacts with
the Crohn’s disease risk gene NOD2 in generating intestinal
epithelial cell responses to bacterial products, and suscep-
tibility to spontaneous colitis in mice with deletion of anti-
oxidant glutathione peroxidase function has been mapped to57
September 2015 Editorial 457a locus containing Duox2. Collectively, these prior studies
together with the current report place DUOX2 as a central
mediator of mucosal immune responses, and suggest that
precise control of DUOX2 expression and activity is required
to maintain homeostasis.
The NOX1 and DUOX2 variants reported in the current
study were discovered in an initial cohort of 59 VEOIBD
patients, but they were not replicated in an independent
cohort of 150 VEOIBD patients. Although it will be
important to test for replication of these speciﬁc variants in
larger VEOIBD cohorts, these results do suggest, as noted
by the authors, that these and other variants in this
pathway in VEOIBD are likely to be quite rare. Moreover, it
is also likely that more comprehensive ongoing whole-
exome sequencing efforts will identify multiple rare
variants that will act together in individual patients to in-
ﬂuence phagocyte and/or intestinal epithelial ROS pro-
duction and host–microbe interactions. This understanding
of an individual patient’s composite genetic load for defects
in ROS production and antimicrobial function will then
likely provide a more focused approach to individualized
therapeutics.
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